Search Bar & Filters
Found 27 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.
Actively Recruiting
Researchers are comparing how long adults with moderate to severe active rheumatoid arthritis RA continue treatment with Upadacitinib UPA versus tumor necrosis factor inhibitors TNFi under real-world conditions in Germany. This observational study includes about 678 participants across approximately 80 sites and aims to understand treatment persistence over time. Participants will receive either Upadacitinib or a TNFi as prescribed by their doctors according to local labels and standard care practices. The choice of treatment is made independently of the study, and the study does not assign treatments but observes patients receiving these therapies in routine care. During the study, participants will be followed for up to 24 months to monitor how long they continue their prescribed treatment. Researchers will collect data on treatment retention rates and other health information during this period. The total study duration, including recruitment and follow-up, is about 48 months.
Actively Recruiting
This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a non-interventional, observational study to understand the long-term use of dupilumab in treating eosinophilic esophagitis EoE among patients aged 12 years and older in Germany. The study aims to describe patients medical history, socio-demographic and disease characteristics, related conditions, prior therapies, and the real-world patterns of dupilumab treatment. It also seeks to assess long-term effectiveness and safety of dupilumab, along with its impact on patients quality of life over two years. Participants in this study are those receiving dupilumab for EoE in routine clinical settings without any treatment intervention from the study team. The observational period for each participant is planned to last approximately two years, during which data on dupilumab use and safety will be collected continuously. This includes tracking treatment details, symptom changes, and any adverse events as reported by physicians and patients. Throughout the study, participants will have their medical, socio-demographic, and disease data analyzed at baseline. Follow-up assessments will record changes in endoscopic scores, esophageal biopsy results, clinical symptoms, food intake behavior, and various quality of life and symptom scales at multiple time points over two years. Hospitalization and sick leave data related to EoE will also be monitored. Safety data will be collected throughout the treatment period to better understand dupilumabs long-term use in real-world practice.
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating how well once-weekly insulin icodec maintains blood sugar levels compared to daily basal insulin injections in adults with type 2 diabetes. The study focuses on people who need to start basal insulin treatment after using other glucose-lowering medications. This phase 4 trial aims to assess insulin icodecs effectiveness in real-world clinical practice over about 13 months. Participants will be randomly assigned to receive either weekly subcutaneous injections of insulin icodec or daily subcutaneous injections of basal insulin analogues such as insulin glargine, detemir, or degludec. The study compares these two insulin regimens as part of standard type 2 diabetes care. Treatment continues during the 52-week period to monitor blood sugar control and treatment satisfaction. Throughout the study, participants will undergo assessments including measuring changes in glycated hemoglobin HbA1c from baseline to week 52. They will also complete questionnaires on treatment adherence, satisfaction, and burden, and researchers will track severe hypoglycemia episodes and insulin doses. The trial spans about 13 months, providing thorough monitoring of treatment impact and safety in daily clinical use.
Actively Recruiting
This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.
Actively Recruiting
Researchers are evaluating whether tralokinumab given as subcutaneous injections along with topical corticosteroids TCS is safe and effective for treating moderate-to-severe atopic dermatitis AD in children and infants. The trial involves two age groups children aged 2 to under 12 years and infants aged 6 months to under 2 years. Children are randomized to receive either tralokinumab plus TCS or placebo plus TCS, while infants receive open-label tralokinumab plus TCS. This Phase 3 trial will last up to four years with visits every two weeks during the first year and every six weeks thereafter, including some phone visits.
1-10 of 27
1